Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28

Chaoxu Zhang(First Hospital of China Medical University), Xiujuan Qu(First Hospital of China Medical University), Ti Wen(Nankai University), Xiaofang Che(First Hospital of China Medical University), Zhi Li(Central Hospital Affiliated to Shenyang Medical College), Shuo Wang(Beijing Tongren Hospital), Min Zhang(Military University), Ce Li(Affiliated Hospital of Hebei University), Kezuo Hou(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Xinye Shao(First Hospital of China Medical University), Yibo Fan(The University of Texas MD Anderson Cancer Center)
Frontiers in Oncology
May 27, 2020
10.3389/fonc.2020.00760
Cited by 71

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417